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Abstract
Suberoylanilide hydroxamic acid (SAHA) is an inhibitor of histone deacetylases (HDACs) used for the treatment of cutaneous
T cell lymphoma (CTCL) and under consideration for other indications. In vivo studies suggest reducing HDAC function can
enhance synaptic function and memory, raising the possibility that SAHA treatment could have neurological benefits. We
first examined the impacts of SAHA on synaptic function in vitro using rat organotypic hippocampal brain slices. Following
several days of SAHA treatment, basal excitatory but not inhibitory synaptic function was enhanced. Presynaptic release
probability and intrinsic neuronal excitability were unaffected suggesting SAHA treatment selectively enhanced
postsynaptic excitatory function. In addition, long-term potentiation (LTP) of excitatory synapses was augmented, while
long-term depression (LTD) was impaired in SAHA treated slices. Despite the in vitro synaptic enhancements, in vivo SAHA
treatment did not rescue memory deficits in the Tg2576 mouse model of Alzheimer’s disease (AD). Along with the lack of
behavioral impact, pharmacokinetic analysis indicated poor brain availability of SAHA. Broader assessment of in vivo SAHA
treatment using high-content phenotypic characterization of C57Bl6 mice failed to demonstrate significant behavioral
effects of up to 150 mg/kg SAHA following either acute or chronic injections. Potentially explaining the low brain exposure
and lack of behavioral impacts, SAHA was found to be a substrate of the blood brain barrier (BBB) efflux transporters Pgp
and Bcrp1. Thus while our in vitro data show that HDAC inhibition can enhance excitatory synaptic strength and
potentiation, our in vivo data suggests limited brain availability may contribute to the lack of behavioral impact of SAHA
following peripheral delivery. These results do not predict CNS effects of SAHA during clinical use and also emphasize the
importance of analyzing brain drug levels when interpreting preclinical behavioral pharmacology.
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Introduction
Histone deacetylases (HDACs) mediate epigenetic changes by
decreasing histone acetylation, leading to condensed chromatin
structure and decreased transcription [1,2]. HDACs can also
impact cellular functions at various levels through deacetylation of
non-histone proteins [3]. SAHA is a HDAC inhibitor that targets
Class I and Class IIb Zn2+-dependent HDACs, causing increased
acetylation. The altered gene regulation induced by SAHA
treatment can arrest proliferation of cancer cells [4]. Also known
as Vorinostat and marketed as Zolinza, SAHA is currently
approved for the treatment of CTCL and is under consideration
for treatment of other malignancies [5–7]. SAHA is also being
considered for non-oncology indications including treatment of
malaria infection and depletion of latent HIV reservoirs during
antiretroviral therapy [8–10]. In the context of brain diseases,
recent studies implicate excess HDAC function in Alzheimer’s
disease (AD) and suggest decreasing HDAC function with drugs
like SAHA could potentially improve cognitive functions [11]. In
particular, HDAC2 has been shown to be upregulated in the
brains of both AD patients and mouse AD models, and knocking
down HDAC2 rescues impaired synaptic plasticity and neurode-
generation-associated memory deficits in an AD mouse model
[12]. Furthermore, while transgenic HDAC2 over-expression
impairs cognitive functions, HDAC2 knockout mice exhibit
enhanced synaptic plasticity and memory function [13]. In
another example, reducing HDAC6 function has been shown to
protect against neurodegeneration induced by oxidative stress and
promote axon outgrowth [14]. As SAHA can block numerous
HDACs including HDAC2 and HDAC6, these observations raise
the possibility that patients taking SAHA could experience
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e69964
neurological impacts. Such impacts could potentially be beneficial
to improve brain function in AD patients. To address this
possibility, we explored the impacts of SAHA treatment on
neuronal function in vitro and on fear memory in AD model mice
and general behavioral activity in wild type mice using the
SmartCubeH System [15–17]. While SAHA enhanced synaptic
transmission and potentiation in vitro, we could not detect any
effect of in vivo treatment on the behaviors measured. Consistent
with a lack of neurobehavioral activity, SAHA exhibited poor




All animal experiments were conducted in accordance with the
National Institute of Health Guide for the Care and Use of
Laboratory Animals. Experiments performed at Genentech were
approved by the Genentech Institutional Animal Care and Use
Committee. Experiments performed at PsychoGenics were
approved by the PsychoGenics Institutional Animal Care and
Use Committee. Experiments performed at Cerebricon were
approved by the National Animal Experiment Board of Finland,
State Provincial Office of Southern Finland.
Slice Cultures
Interface cultures of hippocampal slices were made from 7–8
day old Sprague Dawley rats as previously described [18]. Briefly,
hippocampi were dissected in minimum essential medium (MEM;
Invitrogen, Eugene, OR) with 15 mm HEPES and 10 mm Tris
buffer (Invitrogen). Four-hundred micrometer slices were cultured
on Millicell CM culture plate inserts (Millipore, Temecula, CA).
The culture medium consisted of 50% MEM, 25% HBSS, and
25% horse serum, with 12.5 mM HEPES buffer and penicillin
(100 U/ml)/streptomycin (100 mg/ml) (all from Invitrogen). Cul-
tures were maintained in 5% CO2, at 37uC. Slices were
maintained in vitro for one week prior to transfection.
Electrophysiology
Patch clamp recordings were made in oxygenated Artificial
Cerebrospinal Fluid (ACSF) containing (in mM) 127 NaCl, 2.5
KCl, 1.3 MgSO4, 2.5 CaCl2, 1.25 Na2HPO4, 25 NaHCO3, 25
glucose. For voltage-clamp recordings patch pipette internal
solution consisted of 120 Cs-methanesulfonate, 20 CsCl, 0.5
EGTA, 10 HEPES, 2.5 MgCl2, 4 Na2ATP, 0.3 NA3GTP, 10
Phosphocreatine, and 5 mM QX-314 Br. Miniature excitatory
postsynaptic currents (mEPSCs) were recorded in the presence of
100 mM Picrotoxin (PTX) and 1 mM tetrodotoxin (TTX) at a
holding potential of 270 mV. Miniature inhibitory postsynaptic
currents (mIPSCs) were recorded in the presence of 10 mM 2,3-
Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfon-
amide (NBQX), 50 mM D-(2)-2-Amino-5-phosphonopentanoic
acid (D-AP5) and 1 mM TTX at a holding potential of 0 mV.
Significance of differences between mean frequencies or ampli-
tudes of mEPSCs or mIPSCs were assessed using a student’s t-test.
Cumulative amplitude distributions were plotted at 10 percentile
intervals using values interpolated from 1 pA binned data for each
cell. For experiments measuring open NMDAR block synaptic
inputs were stimulated locally using a bipolar stimulation electrode
and NMDAR EPSCs were isolated using NBQX and PTX and
measured at 270 mV with external MgCl2 lowered to 0.5 mM.
20 mM (5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cy-
clohepten-5,10-imine (MK-801) was then added after a stable
baseline was achieved and synaptic stimulation was resumed. For
synaptic plasticity experiments synaptic inputs were stimulated
locally using a bipolar stimulation electrode and EPSCs were
measured at 270 mV. To isolate glutamatergic synaptic events
and suppress polysynaptic network activity PTX and 10 mM 2-
chloroadenosine were added to the ACSF. After a brief baseline
(about 5 min), a subthreshold LTP induction protocol was
delivered consisting of 100 stimuli at 2 Hz with postsynaptic
neurons voltage-clamped at 0 mV. This protocol was selected
because we have previously found that no LTP is induced in
organotypic slices under basal conditions using this protocol, but
robust LTP can be induced when HDAC2 is genetically reduced
[19]. LTD was induced using 600 stimuli at 2 Hz with
postsynaptic neurons voltage-clamped at 240 mV. Significance
of differences in normalized EPSC amplitudes between treatment
groups following plasticity induction were assessed using a
student’s t-test. For current-clamp recordings internal solution
consisted of 120 K-gluconate, 20 KCl, 0.5 EGTA, 10 HEPES, 2.5
MgCl2, 4 Na2ATP, 0.3 NA3GTP and 10 Phosphocreatine.
Action potential threshold was measured during the smallest
depolarizing current injection steps that triggered spiking. Input
resistance was calculated from the steady-state response to the
smallest hyperpolarizing current injection steps to avoid contam-
ination from hyperpolarization-induced inward currents (h-
current). The h-current ‘‘sag’’ was measured based on the
difference between the maximal and steady-state voltage responses
to strong hyperpolarizing current injection steps. Significance of
differences in all measures between treatment groups were assessed
using a student’s t-test.
Tg2576 Fear Conditioning
Contextual fear conditioning was performed at Cerebricon,
Ltd., (Finland). Tg2576 mice overexpressing human amyloid
precursor protein (APP) with the ‘Swedish’ mutation, K670N/
M671L, under control of the prion promoter, were used. Female
Tg2576 mice were treated once a day for 35 days, starting at
approximately 5 months of age, with i.p. injections of 25 mg/kg
SAHA, 50 mg/kg SAHA or vehicle (DMSO). Injection volume
was 10 ml/kg and testing was done a minimum of 2 hours after
dosing. Open field testing was performed on dosing day 32. Mice
were brought to the experimental room for at least 1 h acclimation
prior to testing in the open field. At least two hours after the last
dosing, mice were placed in open field chambers equipped with
infrared photobeams (Med Associates, Inc., St. Albans VT;
27627620.3 cm) and their locomotor activity was monitored for
30 minutes. Contextual fear conditioning was performed on
dosing days 33–34 using modification of published protocols [20].
The training and testing were conducted on two consecutive days,
using a Coulbourn FreezeFrame system (Coulbourn, Whitehall
PA, USA). Day 33 training consisted of placing a mouse in a
chamber, bright house light on, and allowing exploration for
2 min. Afterward an auditory cue (1700 Hz, 80 dB, the condi-
tioned stimulus) was presented for 15 s. A 2 s foot shock (1.5 mA,
the unconditioned stimulus) was administered for the final 2 s of
the auditory cue. This procedure was repeated, and the mouse was
removed from the chamber 30 s later. Freezing behavior was
recorded during (2 s) and after the shocks (5 s) by a computerized
camera tracking system. The next day, the mouse was returned to
the same chamber in which the training occurred and freezing
behavior was recorded (memory for context). At the end of the
5 min context test, the mouse was returned to its home cage. One
hour later, freezing was recorded in a novel environment (altered
context) and in response to the cue (memory for cue). Freezing
scores for each subject were expressed as a percentage for each
portion of the test (memory for context, altered context, memory
SAHA Brain Effects
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for cue). Reductions in freezing in Tg2576 mice compared to non-
transgenic mice were assessed using a student’s t-test. Effects of
treatment (vehicle, 25 mg/kg or 50 mg/kg SAHA) on freezing or
open field activity in Tg2576 mice were assessed using a one way
ANOVA.
Bioanalysis of SAHA
Liquid chromatographic-tandem mass spectrometry (LC-MS/
MS) was used for the analysis of SAHA. Each brain was
homogenized in water (0.25 g/ml) using a OmniPrep homoge-
nizer (OmniPrep, Las Vegas, NV, USA) and each CSF sample was
collected into mouse plasma (CSF to plasma 1:1, v/v). 25 mL of
plasma, CSF or tissue sample was extracted using acetonitrile and
supernatant was diluted with water and then analyzed using
reversed-phase chromatography with an XB-C18, 5062.1 mm,
5 mm analytical column (Phenomenex). Peak retention time was
1.0 min using the following gradient (time, %B) at flow rate
0.80 mL/min: (0.00 min, 10%) (0.30 min, 10%) (0.60 min, 90%)
(1.10 min, 90%) (1.12 min, 10%) (1.60 min, 10%). Mobile phases
were water with 0.1% formic acid and acetonitrile with 0.1%
formic acid. Mass analysis was conducted on a TSQ Vantage mass
spectrometer (Thermo Scientific, West Palm Beach, FL, USA)
with multiple reaction monitoring (MRM) mode. SAHA was
ionized using an atmospheric pressure chemical ionization (APCI)
source operating in the positive ionization mode. Declustering
potential and collision energy were 65 V and 12 V, respectively.
The MRM transition was m/z 265.3 to m/z 232.2 and the
calibration curve range was between 3.05–20,000 ng/mL for
plasma and brain, and 0.66–2500 ng/mL for CSF. Calibration
curves were fit to a linear regression with 1/62 weighting for all
plasma, brain homogenate and CSF curves.
Enzymatic Assays
A panel of HDAC enzymatic assays (HDAC1 thru HDAC10)
were performed by Nanosyn (Santa Clara, CA) using a Caliper
microfluidics platform with fluorescently labeled peptide sub-
strates. SAHA was serially diluted from a top concentration of
10 mM in DMSO and tested at 12 concentrations with 36dilution
intervals. Final DMSO concentration was 1%. Assays used 0.5–
5 nM enzyme and 1 mM peptide substrates.
SmartCubeH System
SmartCube experiments were conducted at Psychogenics, Inc
(Tarrytown, NY). 10 week old C57BL/6 mice from Taconic
(n = 12/group) were either given a single injection or 14 daily
injections of SAHA or valproate prior to behavioral phenotyping.
On the day of testing, mice were injected with SAHA or valproate
15 minutes prior to testing with the SmartCubeH system [15–17].
The SmartCubeH system can measure numerous spontaneous
behaviors and responses to challenges in the same testing
environment. The hardware includes force sensors and a number
of aversive stimuli used to elicit behavior. Three high-resolution
video cameras provide constant 3D view of the mouse in the
SmartCubeH apparatus throughout the testing period. Digital
videos of the subjects were processed with computer vision
algorithms to extract over 2,000 independent measures including
frequency and duration of behavioral states such as grooming,
rearing, etc., and many other features obtained during the test
session. These data were compared with a database of therapeutic
class signatures. The database comprises 14 classes of drugs with
some of the major classes, such as the antidepressant class,
comprising several subclasses with representatives of most of the
drugs in the market.
In vitro Transporter Assays
Madin-Darby Canine Kidney (MDCK) cells stably transfected
with human MDR1 (Pgp) were obtained from the National
Institutes of Health, (Bethesda, MD) MDCKII cells transfected
with mouse Bcrp1 were obtained from Alfred Schinkel’s lab
(Netherlands Cancer Institute, Amsterdam, Netherlands). Both cell
lines were maintained in Dulbecco’s Modified Eagle Medium
supplemented with 10% FBS and 5 mg/mL Plasmocin and were
harvested with trypsin and seeded on Millipore Millicell-24 well
plates at initial concentrations of 1.306105 cells/mL and
2.506105 cells/mL, respectively. Cell monolayers were equilibrat-
ed in transport buffer (HBSS with 10 mM Hepes, pH 7.4) for 30
minutes at 37uC with 5% CO2 and 95% relative humidity, prior
to the experiment. Dose solutions were prepared in transport
buffer and consisted of SAHA (5 mM) and the monolayer integrity
marker lucifer yellow (100 mM) in the presence and absence of the
MDR1 inhibitor Elacridar (2 mM) or the Bcrp1 inhibitor Ko-143
(1 mM). The dose solutions were added to the donor chambers and
transport buffer (with and without inhibitor) was added to receiver
chambers. The transport of SAHA was examined in the apical to
basolateral (A–B) and basolateral to apical (B-A) directions. The
receiver chambers were sampled (50 mL) at 60, 120, and 180 min
and were replenished with fresh transport buffer after the 60 and
120 min samplings. Lucifer yellow permeability was used as a
marker of monolayer integrity during the experiment. SAHA
concentrations in the donor and receiving compartments were
determined by LC-MS/MS analysis. The apparent permeability
(Papp) in the apical to basal A–B and basal to apical B-A directions,
was calculated as follows: Papp = (dQ/dt)N(1/AC0), where: dQ/
dt = rate of compound appearance in the receiver compartment;
A=Surface area of the insert; and C0= Initial substrate concen-
tration at T0. The efflux ratio (ER) was calculated as (Papp B–A/
Papp A–B).
Results
In vitro SAHA Treatment Enhances Excitatory Synaptic
Function
Previous studies have reported that HDAC inhibitors can alter
synaptic function when applied to acutely prepared brain slices for
as little as 10–90 minutes [21–23], a time frame that is unlikely to
involve effects of transcriptional alterations due to HDAC
inhibition. We wanted to explore the consequences of ongoing
exposure to SAHA so as to better reflect therapeutic dosing which
is expected to include transcriptional changes that could take
hours or days to become evident. Therefore we used organotypic
hippocampal brain slices that were treated with 0.5 mM SAHA for
3–4 days prior to assessing synaptic function. First we examined
spontaneous miniature excitatory and inhibitory postsynaptic
currents (mEPSCs and mIPSCs) in CA1 pyramidal neurons
following treatment with SAHA or vehicle (DMSO). These
experiments revealed an increase in the amplitude but not
frequency of mEPSCs, indicating enhanced excitatory synaptic
strength following SAHA treatment (Figure 1A). On the other
hand, no changes in the amplitude or frequency of mIPSCs were
detected (Figure 1B). These results indicate SAHA treatment
enhances excitatory synaptic transmission without affecting
inhibitory synaptic transmission. Thus, while SAHA could
potentially cause multiple impacts on synaptic function via
inhibition of various individual HDAC isozymes, the net impact
of several days of pan-HDAC inhibition, including any compen-
satory responses, is manifested as a selective enhancement of basal
excitatory synaptic function.
SAHA Brain Effects
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Presynaptic Function and Intrinsic Excitability are
Unaffected by in vitro SAHA Treatment
The increased amplitude but not frequency of mEPSCs is
consistent with postsynaptic rather than presynaptic changes
following SAHA treatment. To test whether presynaptic functions
are altered by SAHA, we measured parameters that are sensitive
to alterations in presynaptic release probability. First we examined
short-term plasticity, including paired-pulse facilitation at short
inter-stimulus intervals, and paired-pulse depression at longer
inter-stimulus intervals, measures that are dependent on presyn-
aptic release probability [24]. These recordings showed no
differences in paired-pulse facilitation or paired-pulse depression
between SAHA and vehicle treated slices (Figure 2A). Second we
examined the rate of use-dependent blockade of isolated
NMDAR-mediated EPSCs by the NMDAR open channel blocker
MK-801. The rate of blockade by MK-801 is dependent on
presynaptic release probability and hence serves as another read-
out of presynaptic function. The rate of blockade also did not show
any difference between SAHA and vehicle treated slices
(Figure 2B). Together these results support the conclusion that
the enhanced mEPSC amplitudes result from postsynaptic
alteration in the absence of any significant changes to presynaptic
release probability. To look for non-synaptic alterations following
SAHA treatment, we examined the intrinsic excitability of CA1
neurons. No changes were observed in: 1) the number of action
potentials evoked by various levels of current injection; 2) action
potential threshold; 3) input resistance; or 4) the membrane sag
caused by hyperpolarization-activated inward currents (Figure 3).
Together these results suggest that SAHA does not alter intrinsic
neuronal excitability.
In vitro SAHA Treatment Augments LTP and Blocks LTD
We tested whether treating slice cultures with SAHA for several
days could alter synaptic plasticity. Robust LTP was observed in
SAHA-treated slices using a subthreshold LTP-induction protocol
that did not evoke significant synaptic potentiation in vehicle-
treated slices (Figure 4A). This indicates that SAHA treatment can
lower the threshold for inducing LTP. On the other hand no LTD
was observed in SAHA-treated slices using an induction protocol
that caused significant LTD in vehicle-treated slices (Figure 4B),
indicating SAHA treatment blocks LTD induction and/or
expression. Together these results demonstrate that SAHA
treatment alters synaptic plasticity in a manner that enhances
potentiation and limits depression of excitatory synapses.
In vivo SAHA Treatment does not Rescue Fear
Conditioning Deficits in Tg2576 Mice
LTP is considered to be a key substrate of memory formation
[25,26] and the hippocampus plays a critical role in contextual
fear memory [27,28]. Tg2576 AD model mice exhibit impaired
Figure 1. Excitatory synaptic function is selectively enhanced in CA1 of hippocampal brain slices following in vitro SAHA treatment.
(A) The median amplitude of mEPSCs was significantly increased in SAHA-treated slices (p,0.05, n = 14 vehicle, 14 SAHA), while there was no
significant change to mEPSC frequency as measured by the median interval between events (p.0.05). Example mEPSC traces from vehicle and SAHA
treated slices are shown inset (scale bar represents 10 pA and 250 ms). (B) SAHA treatment did not significantly alter the amplitude or frequency of
mIPSCs (p.0.05, n = 14, 11). Example mIPSC traces from vehicle and SAHA treated slices are shown inset (scale bar represents 10 pA and 500 ms). All
data points are plotted as mean 6SEM.
doi:10.1371/journal.pone.0069964.g001
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contextual fear conditioning that correlates with impaired
hippocampal LTP [29]. Therefore the enhanced LTP seen in
the hippocampus following in vitro treatment with SAHA could
potentially translate into improvement of contextual fear condi-
tioning in the Tg2576 mice. Furthermore, previous studies have
suggested that HDAC inhibition using various pan-HDAC
inhibitors can rescue deficits in contextual fear conditioning in
AD models [30–33], and SAHA injection in particular has been
reported to enhance fear memory [13,30]. Therefore we tested if
treatment with SAHA could rescue the robust deficits in fear
memory seen in the Tg2576 mice (Figure 5A). To reflect ongoing
therapeutic dosing, mice were given daily i.p. injections of 25 or
50 mg/kg SAHA or vehicle for 35 days and were tested for
conditioned fear memory during the final days of dosing.
Surprisingly, these experiments did not reveal any improvement
of contextual fear memory, with no effect of SAHA treatment on
the time spent freezing in response to either the conditioned
context or the conditioned cue (Figure 5B). Freezing in response to
the unconditioned stimulus (foot shock) was also unaffected
(Figure 5C), indicating that SAHA did not alter the response to the
shock. Locomotor activity can be a confound in fear conditioning
experiments, so we also examined activity in the open field, but
again saw no effect of SAHA treatment (Figure 5D). One potential
explanation for the lack of behavioral impact of in vivo SAHA
treatment is poor CNS exposure of SAHA following peripheral
delivery. Therefore we analyzed the concentration of SAHA in
samples taken from the 50 mg/kg treatment group 1 hour post
injection on day 35 of treatment. These measurements revealed
that while total plasma levels of SAHA were 1.5360.80 mM, and
CSF levels were 0.6160.38 mM, levels in the brain were below the
lower limit of quantification (LLOQ) of 0.17 mM in these samples.
This bioanalysis suggests poor pharmacokinetic properties of
SAHA could potentially explain the lack of efficacy.
SAHA has Limited Brain Availability Following Peripheral
Administration
To better understand the bioavailability of SAHA we performed
a pharmacokinetic study of the time course of both total and
unbound SAHA concentrations in the plasma, CSF, and brain
following 50 mg/kg i.p. injections (Figure 6A). This analysis
revealed: 1) a significant amount of SAHA was bound to protein
Figure 2. Measures reflecting presynaptic function are normal
in SAHA treated slices. (A) The paired-pulse ratio (PPR; amplitude p2/
p1) was not significantly different at 50, 100, 200, 400 or 800 ms
intervals between stimuli in SAHA vs vehicle treated slices (p.0.05,
n = 5 vehicle, 4 SAHA). Example vehicle EPSCs are shown inset (scale bar
represents 20 pA and 100 ms). (B) The rate of NMDAR EPSC blockade by
MK-801 during repetitive stimulation was not different between SAHA
vs vehicle treated slices. (p.0.05, n = 7 vehicle, 7 SAHA). Example
vehicle NMDA EPSCs are shown inset (scale bar represents 50 pA and
20 ms). Data are plotted as mean 6SEM.
doi:10.1371/journal.pone.0069964.g002
Figure 3. Intrinsic membrane properties are unaltered by
SAHA treatment. (A) Representative traces from vehicle (black) and
SAHA (red) treated slices during a series of hyperpolarizing and
depolarizing current injection steps (scale bar represents 20 mV and
100 ms). There was no difference between vehicle and SAHA treated
slices in the number of action potentials elicited by 500 ms current
injection pulses at any of the current injection levels (p.0.05, n = 7,7).
(B) Action potential threshold, input resistance, and membrane sag
reflecting the hyperpolarization-induced inward current, were all
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(40.7% plasma, 87.0% brain); 2) SAHA was rapidly cleared and
undetectable in the brain at time points beyond 1 hour
(LLOQ=0.018 mM); and 3) brain levels of SAHA were much
lower than plasma levels, with total and free brain-to-plasma ratios
of 0.04 and 0.01 respectively (area under the curve up to the last
measureable time point; AUClast ratios). To determine if a higher
dose could enhance brain exposure, pharmacokinetic analysis was
repeated following 150 mg/kg SAHA injections (Figure 6B).
While the higher dose did not increase the maximal observed
concentration (Cmax) of free SAHA in the brain (0.1160.02 mM
for 50 mg/kg vs 0.1060.01 mM for 150 mg/kg), the AUClast was
increased from 0.07 to 0.36 hr?mM. Overall the pharmacokinetic
analysis demonstrates low brain concentrations of free SAHA, and
shows that increasing the dose can prolong SAHA exposure but
does not enhance the peak concentration achieved in the brain.
SAHA Inhibits Different HDAC Isozymes with variable
Potency
To help interpret the potential impact of the free brain SAHA
concentrations achieved by in vivo SAHA injection, we examined
the potency of SAHA against the different HDAC isozymes as
determined by in vitro enzymatic assays (Table 1). Based on this
data, the free brain SAHA Cmax of 0.11 mM (which was transiently
achieved in the in vivo pharmacokinetic studies) exceeded the IC50
values of the Class I HDACs, HDAC1 (0.061 mM) and HDAC3
(0.019 mM) but did not reach the IC50 values of HDAC2
(0.251 mM) or HDAC8 (0.827 mM). The IC50 values of all of the
class IIa HDACs were far greater than the in vivo Cmax with
values all .10 mM. On the other hand the class IIb HDACs had
very low IC50 values with the Cmax of the in vivo studies above the
IC50 for both HDAC6 (0.009 mM) and HDAC10 (0.029 mM).
Moreover the free brain concentrations remained above the
HDAC6 IC50 for at least 6 hours after the 150 mg/kg dose.
Overall these results suggest in vivo injections do not result in
significant inhibition of the HDAC2 isozyme that is critically
involved in fear memory and in deficits in AD model mice [12,13].
Furthermore, the in vivo injections of SAHA could only transiently
impact a subset of the other HDAC isozymes with the exception of
HDAC6, which could potentially be inhibited for a more
prolonged period following higher SAHA doses. In contrast the
continuous exposure of brain slices to 0.5 mM SAHA in our in vitro
studies should be sufficient to broadly inhibit all of the class I
HDAC isozymes, including HDAC2, as well the Class IIb
isozymes.
High-content Phenotyping does not Reveal a Significant
Neurobehavioral Impact of in vivo SAHA Treatment
That the free brain concentration of SAHA did not even briefly
reach the IC50 of HDAC2 which is thought to be critical in fear
memory and memory impairments in AD model mice [12,13] is
consistent with the lack of improvement of fear memory observed
in the Tg2576 mice. Nonetheless, given the expected effects of
HDAC inhibition on gene transcription, it is possible that even a
transient inhibition of the other class I HDACs or Class IIb
HDACs could be sufficient to result in some behavioral impacts,
especially at higher doses or after prolonged treatment. Therefore,
to broadly asses any behavioral effects of SAHA in C57BL/6 mice
we employed high-content behavioral phenotyping using the
SmartCubeH technology [15–17]. This technology assesses
behavioral responses to test compounds and determines the class
of CNS activity corresponding to any observed behavioral activity.
For this study 50 mg/kg or 150 mg/kg doses of SAHA were given
to wild type mice prior to SmartCubeH testing. A known
behaviorally relevant dose of valproate (225 mg/kg) was used as
a positive control for the sensitivity of the assay, although it should
be noted that this drug has activity on many different targets, and
its impacts on behavior should not be assumed to be due to HDAC
inhibition. Groups of mice were tested following a single injection
or following 14 days of injections to allow for any chronic effects of
treatment to develop. There were no significant behavioral
alterations observed following single injections of 50 mg/kg or
150 mg/kg SAHA (Figure 7A). Following chronic treatment, the
only significant behavioral activity detected for SAHA was in the
lower dose group and did not correspond to the signature of any
known pharmacological class (Figure 7B). The lack of any
behavioral activity in the higher SAHA dose group argues against
the unclassified activity in the lower dose group reflecting a CNS
effect of chronic SAHA treatment. In contrast, valproate showed
strong anxiolytic and mild psychostimulant class behavioral
Figure 4. SAHA treated slices exhibit enhanced induction of
LTP and impaired LTD. (A) An induction protocol that was
subthreshold in vehicle treated slices readily evoked LTP in SAHA
treated slices (p,0.05, n = 5,5). Example traces before and after LTP
induction are shown in red for SAHA and black for vehicle treated slices
(scale bars represent 20 pA and 20 ms). (B) An induction protocol that
readily induced LTD in vehicle treated slices could not produce LTD in
SAHA treated slices (p,0.05, n = 9 vehicle, 8 SAHA). Example traces
before and after LTD induction are shown in red for SAHA and black for
vehicle treated slices (scale bars represent 25 pA and 20 ms). Data are
plotted as mean 6SEM.
doi:10.1371/journal.pone.0069964.g004
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activity after acute treatment (Figure 7A) and also exhibited a
strong anxiolytic activity signature in chronically treated mice,
confirming sensitivity of this assay (Figure 7B). Overall these results
do not support a behavioral effect of up to 150 mg/kg SAHA
following acute or chronic i.p. injections.
SAHA is a Substrate of Brain Efflux Transporters
Given the lack of behavioral impacts of SAHA, we wanted to
better understand the causes of limited free SAHA in the brain.
One possibility is that low levels of SAHA in the brain could be
due to active export of this drug across the BBB. To test if SAHA is
a substrate of brain efflux transporters we performed in vitro
transporter assays using monolayers of MDCK cells expressing
human P-glycoprotein (Pgp; Multidrug Resistance Protein 1) or
mouse Breast Cancer Resistance Protein (Bcrp1), two important
ATP-binding cassette (ABC) gene family members that are present
in the BBB and often limit drug exposure in the brain [34,35]
(Figure 8A). These experiments showed efflux ratios for SAHA of
1260.75 for Pgp and 1460.86 for Bcrp1 compared to ratios of
1.460.64 and 1.260.13 in the presence of the respective
transporter inhibitors (Figure 8B). These results suggest SAHA is
a substrate of both Pgp and Bcrp1 and that active efflux likely
makes a major contribution to the low brain distribution of SAHA
following peripheral delivery.
Discussion
Our in vitro electrophysiological analysis using cultured brain
slices demonstrates that directly treating brain tissue with SAHA
can impact both basal synaptic function and synaptic plasticity.
The enhanced mEPSC amplitude but not frequency, together with
unchanged short-term plasticity and use-dependent NMDAR
blockade rate, strongly support a postsynaptic enhancement of
excitatory synapses. At the same time we did not detect changes to
inhibitory synaptic transmission, which suggests SAHA treatment
Figure 5. Fear memory deficits in Tg2576 mice are not rescued by SAHA treatment. A) Compared to non-transgenic littermates (n = 15),
Tg2576 (n = 14) mice showed significantly less freezing than wt mice when returned to the context in which conditioning occurred (context,
p,0.001), when placed in an altered context (altered, p,0.01), or in response to the cue used for conditioning (cue, p,0.05). B) Tg2576 mice were
treated daily for 33 days prior to, as well as during fear conditioning with either vehicle (n = 14), 25 mg/kg SAHA (n= 13), or 50 mg/kg SAHA (n= 13).
There was no effect of treatment on the percentage of time Tg2576 mice spent freezing in response to the context, altered context, or cue (p.0.05).
C) There was no effect of treatment on the percentage of time spent freezing during conditioning (p.0.05). D) There was no effect of treatment on
the distance traveled in the open field test (total distance= 38.067.7 m for vehicle, 39.666.1 m for 25 mg/kg SAHA, and 34.265.2 m for 50 mg/kg
SAHA, p.0.05). All data are plotted as mean 6SEM.
doi:10.1371/journal.pone.0069964.g005
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leads to an overall shift in the balance between excitation and
inhibition in the neural network. These results are consistent with
studies of HDAC2 KO mice that show increased spine density in
CA1 pyramidal neurons, which has been interpreted as reflecting
increased excitation and attributed to HDAC2 regulation of genes
involved in synapse formation and plasticity [13]. At the same time
it is important to keep in mind that the state of synaptic and
neuronal function measured after several days of drug treatment
reflects the combined effects of inhibiting multiple HDAC
isozymes by SAHA, as well as any potential network-wide
compensatory processes. For example we have recently reported
that selective HDAC2 knockdown in individual neurons in this
preparation not only enhances excitation, but also reduces
GABAergic synaptic inhibition in a cell-autonomous manner
[19]. The lack of a change in synaptic inhibition observed after
several days of SAHA treatment suggests that either blockade of
isozymes other than HDAC2 enhance inhibition so as to negate
HDAC2-mediated reductions, and/or that network-wide com-
pensatory mechanisms counteract any initial cell-autonomous
changes in synaptic inhibition. Thus while we cannot discriminate
isozyme-specific contributions to the neurophysiologcal alterations
observed following SAHA treatment, the net impact of SAHA
treatment, is an altered functional state of the network featuring
enhanced excitation.
Our in vitro brain slice experiments also showed that, similar to
observations of enhanced LTP following very acute treatment with
SAHA or other pan-HDAC inhibitors [21–23], enhanced LTP
occurs during more prolonged HDAC inhibition. Furthermore we
Figure 6. Pharmacokinetic analysis of SAHA following i.p. injection. A) Bioanalysis of the time course of total (top) and unbound (bottom)
plasma, CSF, and brain levels of SAHA following a single 50 mg/kg ip injection (n = 3 mice/time point). The dotted red lines represent the SAHA
concentration imposed on the in vitro slice cultures for the electrophysiological studies. B) Total (top) and unbound (bottom) SAHA levels are shown
following a 150 mg/kg ip injection (n = 3/time point). All data is shown as mean 6 SD.
doi:10.1371/journal.pone.0069964.g006
Table 1. SAHA IC50 values for each HDAC isozyme are shown as measured using in vitro enzymatic assays.
Class I Class IIa Class IIb
HDAC1 HDAC2 HDAC3 HDAC8 HDAC4 HDAC5 HDAC7 HDAC9 HDAC6 HDAC10
IC50(mM) 0.061 0.251 0.019 0.827 .10 .10 .10 .10 0.009 0.029
(CI) (0.004) (0.016) (0.001) (0.078) (0.001) (0.002)
Values are in mM and confidence intervals are in parentheses.
doi:10.1371/journal.pone.0069964.t001
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extended the examination of synaptic plasticity to LTD and found
that SAHA treatment impaired this form of synaptic plasticity.
Therefore in addition to enhancing basal excitatory synaptic
transmission, in vitro SAHA treatment also makes it easier to
potentiate excitatory synapse and harder to weaken them, thus
shifting the balance towards synaptic potentiation/stabilization
rather than weakening/elimination. Overall these results predict
that HDAC inhibition will promote excitation and network
activity, which could be beneficial in cases of cognitive impairment
featuring weakened synaptic function, reduced synaptic potenti-
ation, and loss of excitatory synapse, as is the case in mouse models
of AD.
Despite expectations from previous studies of contextual fear
conditioning using the HDAC inhibitor phenylbutyrate in Tg2576
mice [31], or using various HDAC inhibitors including SAHA in
double transgenic AD model mice (over-expressing the same
‘swedish’ mutant APP as the Tg2576 mice as well as mutant
presenilin 1) [30], we did not observe a significant rescue of
contextual fear conditioning in Tg2576 mice treated with 25 mg/
kg or 50 mg/kg SAHA. Bioanalysis of samples taken from these
mice 1 hour after dosing on day 35 of daily injections revealed that
SAHA levels were low in the CSF and undetectable in the brain.
Detailed pharmacokinetic analysis demonstrated high binding,
rapid clearance and very low levels of free SAHA in the brain.
Consistent with the low levels of free SAHA that were only
transiently detectable in the brain, in vitro transporter assays
showed that SAHA is a substrate for the brain export transporters
Pgp and Bcrp1. While previous studies have proposed that brain
SAHA exposure could be increased by using a vehicle that
enhances solubility [36], our results suggest peripheral delivery of
SAHA will be hampered in achieving brain exposure due to active
export across the BBB regardless of peripheral solubility.
Based on our in vitro enzymatic assay results, peak free brain
levels would appear insufficient to significantly impact HDAC2,
HDAC8 or any of the Class IIa HDACs. However other reports
using in vitro assays have sometimes reported higher potency for
SAHA (with IC50 or Ki values in the 1–200 nM range compared
to our IC50 of 251 nM for HDAC2, for example) [37–39], which
emphasizes the dependence of potency measurements on in vitro
assay conditions, and the uncertainty over the precise potency of
in vivo SAHA for HDACs in the brain. In addition, based on our
in vitro assays, the free brain levels did at least transiently exceed
the IC50 values for HDAC1, HDAC3, HDAC6, and HDAC10.
Therefore, taken together with reports of increased histone
acetylation following peripheral delivery of SAHA [36,40], this
suggests that despite limited availability of free drug, some degree
of target engagement for some HDAC isozymes may occur in the
brain. While the roles of HDACs other than HDAC2 in
neurobehavior are not well understood, it is possible their
inhibition could affect behavior of wildtype mice even if HDAC2
is not significantly inhibited. However, broadly screening for
effects of SAHA injections in wildtype mice using the SmartCubeH
system failed to detect any impact of SAHA: no relevant
neurobehavioral activity consistent with any class of drug action
was evident following either a single injection or 14 days of dosing
with 50 mg/kg or 150 mg/kg SAHA. Overall the lack of efficacy
in Tg2576 mice or any behavioral impacts in wt mice is likely
contributed to by the very poor pharmacokinetic profile of SAHA
in the brain. However, from our data we cannot exclude the
possibility that sufficient HDAC inhibition is achieved to result in
significant alteration in histone acetylation levels, but there is
simply no effect of such altered acetylation on the behavioral
assays we conducted.
Our observations of low free SAHA in the mouse brain and no
behavioral impact of SAHA following peripheral injection are at
odds with previous studies reporting enhanced contextual fear
conditioning memory in mice following peripheral SAHA delivery
[13,30]. At the same time it is worth noting that our results do not
contradict the broader pharmacological evidence for a role of
HDACs in memory, as enhanced contextual fear memory has
been demonstrated using various other HDAC inhibitors which
likely have distinct pharmacokinetic properties from SAHA
[22,30–33,41,42]. In addition, studies using direct infusion of
SAHA into the brain [21,43], or genetic reduction of HDAC
isozymes [12,13] have also demonstrated the importance of
HDAC function in memory formation. Therefore our in vitro
results are in agreement with previous studies suggesting HDAC
inhibition impacts synaptic function, but our in vivo results argue
Figure 7. Acute or chronic SAHA treatment does not produce
significant drug class activity signatures as assessed by the
SmartCubeH. A. Groups of mice were treated acutely with a single
injection of 50 mg/kg or 150 mg/kg SAHA or vehicle. In addition, a
group was treated with valproate (225 mg/kg). Both does of SAHA were
behaviorally inactive without a clear therapeutic signal. In contrast
valproate was behaviorally active (p,0.001, discrimination in-
dex = 100%) with a strong anxiolytic signature and a mild psychostim-
ulant signature. B. Groups of mice were treated daily for 14 days with
SAHA or Valproate. While the lower dose of SAHA appeared
behaviorally active (p,0.001, discrimination index= 88%), the activity
was not consistent with any known therapeutic signal and the higher
dose was not behaviorally active. In contrast valproate showed a strong
behavioral activity (p,0.001, discrimination index = 98%) with a
predominantly anxiolytic signature. C. The legend shows the 15 classes
of behavioral activity that were assessed.
doi:10.1371/journal.pone.0069964.g007
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against the usefulness of SAHA in particular in causing such
impacts in vivo, which is relevant given the clinical use of this
compound. Our results also emphasize that the interpretation of
behavioral pharmacology data should always include careful
analysis of brain drug levels in order to identify true negative
results and eliminate false positive results.
It is worth noting that compromised BBBs could allow brain
effects of SAHA not seen in our in vivo studies. For example SAHA
has been reported to be efficacious in models of glioblastoma
[44,45] and is currently being tested in clinical trials for patients
with brain tumors. One possibility is that the efficacy of SAHA in
preclinical glioma models is facilitated by compromised BBB
function in the area of the tumor. Supporting this, tumor cells have
been demonstrated to induce changes in the composition of the
basal lamina and in astrocytic components of the neurovascular
unit and increase vascular permeability in mouse brains [46,47].
Thus while our results do not predict a neurological impact of
SAHA in CTCL patients, who are unlikely to have compromised
BBBs, it is plausible that SAHA would be more available in the
brain of glioblastoma patients. At the same time, our results
suggest that in addition to issues with toxicity during chronic
dosing, SAHA is also unlikely to be efficacious in neurological
conditions such as AD which generally feature intact BBB
function. The finding of limited access of SAHA to the brain
also has implications beyond neurological indications. For
example, given recent excitement around using SAHA to disrupt
HIV latency in order to eradicate infection [8], our results suggest
it will be critical to consider the extent of HIV brain reservoirs
[48,49]. Overall our results highlight that while HDAC inhibition
can impact neuronal function, efforts to develop HDAC inhibitors
for targeting CNS indications need to focus not only on reducing
toxicity and achieving selectivity, but also on avoiding compounds
that are substrates for efflux transporters in order to allow
adequate brain exposure.
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